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Abstract
Background: Availability of oxygen and nutrients in the coronary circulation is a crucial determinant of cardiac
performance. Nutrient composition of coronary blood may signiﬁcantly vary in speciﬁc physiological and pathological
conditions, for example, administration of special diets, long-term starvation, physical exercise or diabetes. Quantitative
analysis of cardiac metabolism from a systems biology perspective may help to a better understanding of the
relationship between nutrient supply and eﬃciency of metabolic processes required for an adequate cardiac output.
Results: Here we present CardioNet, the ﬁrst large-scale reconstruction of the metabolic network of the human
cardiomyocyte comprising 1793 metabolic reactions, including 560 transport processes in six compartments. We use
ﬂux-balance analysis to demonstrate the capability of the network to accomplish a set of 368 metabolic functions
required for maintaining the structural and functional integrity of the cell. Taking the maintenance of ATP,
biosynthesis of ceramide, cardiolipin and further important phospholipids as examples, we analyse how a changed
supply of glucose, lactate, fatty acids and ketone bodies may inﬂuence the eﬃciency of these essential processes.
Conclusions: CardioNet is a functionally validated metabolic network of the human cardiomyocyte that enables
theorectical studies of cellular metabolic processes crucial for the accomplishment of an adequate cardiac output.
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Background
Cardiovascular diseases are the main cause of death
worldwide [1]. The myocardium, comprised of cardiomy-
ocytes, has to fulﬁl a wide range of metabolic functions
serving cellular integrity and energy demand to maintain
contractile activity for the cardiac cycle. Consequently,
alterations in the metabolism of cardiomyocytes have a
great impact on the cyclical contraction of the heart.
More insights into the metabolic changes and eﬃ-
ciency of cardiomyocytes under conditions of heart failure
and myocardial hypertrophy may improve treatments
of these diseases. A prerequisite for such an approach
is the reconstruction of the metabolic network of the
human cardiomyocyte. Previous genome-scale metabolic
network reconstructions [2-4] have shown their capacity
to enable an insight into metabolic changes in altered
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extra- and intracellular conditions. Computational meth-
ods [5-8] oﬀer the possibility to simulate metabolic
responses in restricted substrate supply or inhibition of
enzymatic reactions observed in diabetes, obesity, star-
vation and cardiovascular diseases. Most importantly
the metabolic eﬃciency of cardiomyocytes to maintain
mechanism, which are directly or indirectly involved
in cardiac contraction could be studied, including the
synthesis of ﬁlament proteins, ion channels and mem-
brane phospholipids as well as energy production and
storage. The metabolic eﬃciency of cardiomyocytes to
maintain continuous ATP demand for muscular con-
traction, replenish and eventually increase, the biosyn-
thesis of macromolecules depends upon the availability
of oxygen and external substrates, including fatty acids,
glucose, lactate, pyruvate and amino acids [9]. Among
these, fatty acids are the preferred substrate, however
the contribution of each substrate to metabolic pro-
cesses is greatly dependent on the cellular state (cell
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cycle), oxygen supply and endocrinological conditions
[10,11]. Recent investigations demonstrated that the fatty
acid composition of myocardial membrane phospholipids
alters with dietary uptake of fatty acids and oxygen sup-
ply [12,13]. An increased incorporation of long-chain
omega-3 polyunsaturated fatty acids (e.g. eicosapen-
taenoic acid, docosahexaenoic acid), mostly derived from
dietary essential alpha-linoleic acid (18:3 n-3, ALA) [14],
seems to have beneﬁcial eﬀects against the risk of primary
cardiac arrest [15,16]. Furthermore structural adaptation
to hypoxia [12], thus oﬀers protection from oxidative
damage.
Diabetes and obesity have been especially shown to
be associated with oxidative stress [17] and damage by
reactive oxygen species (ROS) to proteins, nucleic acids
and phospholipids such as cardiolipin [18]. The mito-
chondrial membrane of cardiomyocytes comprises an
extraordinary high content of cardiolipin, which cannot
be replaced by other phospholipids [19]. Furthermore,
cardiolipin is indispensable for the activity of rate-limiting
protein complexes in mitochondrial ATP production such
as adenine nucleotide translocase [20], F0F1-ATPase [21]
or complex I. The latter is considered a source of cel-
lular ROS, which in turn can induce cardiolipin dam-
age and, consequently, decrease cardiac functionality
[18].
In addition to permanent utilization of substrates, car-
diomyocytes are able to store energy-rich substrates,
which prevents myocardial injury in hypoxic or ischemic
conditions. An important short-term store is glycogen.
The formation is strongly dependent upon nutritional
composition of the blood. In particular, a reduction
of free fatty acids in plasma by nicotinic acid treat-
ment was found to lower levels of cardiac glycogen
in rats [22]. This remarkable ﬁnding, considering that
glycogen cannot be formed from free fatty acids,
underlines the importance of a holistic approach to
the study of cardiomyocyte metabolism taking into
account all metabolic processes involved in glycogen
synthesis.
The aim of the present investigationwas to reconstruct a
genome-scale metabolic network of the human cardiomy-
ocyte. Using methods of constraint-based optimization,
we demonstrate how changes in oxygen and substrate sup-
ply inﬂuence the eﬃciency of selectedmetabolic functions
of cardiomyocytes and provide valuable suggestions for
substrate compositions allowing optimal accomplishment
of metabolic functions to provide cellular integrity and
maintain cardiac work.
Results
First, we reconstructed the metabolic network of the
human cardiomyocyte (CardioNet) and tested physiolog-
ical functions of the cardiomyocyte to ensure full func-
tionality and consistency of the network. Furthermore,
we compared our network to two previously reported
mitochondrial networks [23,24] and one genome-scale
reconstruction of the human heart [25].
Second, we determined substrate and oxygen require-
ment in varied availability of four diﬀerent substrates
while satisfying a baseline ATP consumption rate. We
further analysed the eﬃciency of these varied substrate
compositions and compared our ﬁndings to experimental
results.
Finally, we performed an extensive simulation of varied
availability for nine diﬀerent substrates while satisfying a
complex target function of the cardiomyocyte and anal-
ysed the eﬃciency.
Metabolic network for the human cardiomyocyte
We developed a fully compartmentalized network of
the human cardiomyocyte, which accomplishes various
sets of physiological functions of the human heart. The
network totals 1793 reactions, including 560 transport
reactions and 728metabolites assigned to 6 diﬀerent com-
partments: extracellular, cytosol, mitochondrion, micro-
some, lysosome and peroxisome (see Table 1). At the
current state the synthesis of biopolymers such as DNA
and RNA is not part of the metabolic network, there-
fore no reactions were considered in the network recon-
struction which are localisied in the nucleus, e.g. DNA
transcription and translation. Instead we restrain the
objectives of the metabolic network to the production of
building blocks, e.g. amino acids and nucleotides. Any
changes in enzyme activity or occurrence, such as in e.g.
heart failure, have to be included as constraints into the
optimization problem.
Furthermore, the network includes nine generic
metabolites (pooled metabolites, [4]) which describe
compounds with variable composition and appear only in
reactions for lipoprotein particles, such as LDL particles
(see Additional ﬁle 1).
Moreover, we included the metabolism of distinct
fatty acids, glycerolipids, glycerophospholipids and sph-
ingolipids, as far as we could ﬁnd biochemical evidence
for their occurrence in the human heart (see Additional
ﬁle 2), as well as cross-references from online databases,
such as Lipid Maps Classiﬁcation System [26] and Human
Metabolome Database [27].
Table 1 Overview of themetabolic network of human cardiomyocyte
Compartments Reactions Transporters Metabolites Literature references Genes
amount 6 1793 560 728 363 2565
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To ensure consistency and full functionality of the
metabolic network, we performed a testing of physi-
ological functions based on knowledge of the cardiac
metabolism by using ﬂux balance analysis (FBA) (see
Methods). The required functions included phospholipid
synthesis (e.g. cardiolipin), conversion of amino acids
into citric acid cycle intermediates by transamination or
oxidative deamination as well as nucleotide synthesis (see
Table 2, Additional ﬁle 3 and 4).
The import of metabolites during these simulations was
restricted to oxygen, glucose, lactate, ketone bodies (ace-
toacetate, (R)-3-hydroxybutanoate), essential amino and
fatty acids as well as vitamins, while the release of interme-
diates were restricted to metabolic end products, e.g. lac-
tate and glutamine (see Additional 3). In case the network
failed to fulﬁl a required function, we critically evaluated
related reactions and metabolites for producibility.
Primary missing intracellular transport reactions
and incomplete pathways (e.g. lipid metabolism) were
revealed, which required further manual literature review
to complete the network functionality. We revised reac-
tions and eventually included new reactions into the
metabolic network based on additional evidence for
occurrence in the human cardiomyocyte from e.g. exper-
imental studies (see Additional ﬁle 2). The resulting
metabolic network (CardioNet) and a complete list of
all metabolites is provided with the Additional ﬁle (see
Additional ﬁle 1 and 5).
In a next step we compared the metabolic network
to previously reported reconstructions of the mitochon-
drion in cardiomyocytes [23,24] and one genome-scale
reconstruction of the human heart [25]. All models used
diﬀerent types of evidence for the network reconstruc-
tion process (e.g. transcriptomic, metabolomic, proteomic
data) similar to this study. In contrast both mitochon-
drial networks [23,24] and this study are cross-references
from experimental studies or other database not pro-
vided in the genome-scale reconstuction of the human
heart [25]. We found a large alignment between Car-
dioNet and bothmitochondrial networks with 90.48% and
92.49% of the mitochondrial network reactions are rep-
resented in CardioNet. In contrast to our model heme
biosynthesis is considered to more detail in these net-
works and arginase II reaction is included. There is
evidence for absent expression of arginase II in the
normal human cardiomyocyte [66] with up-regulation
only during pathological states such as heart failure [67].
The current network reconstruction is based on evi-
dence in the normal human cardiomyocyte, thus reactions
(e.g. arginase II) which belong to genes which are not
expressed normally, have to be included into the network
to study speciﬁc pathological conditions. The metabolic
network of the human cardiomyocyte (CardioNet) con-
siders 228 additional mitochondrial reactions which are
not part of the previous mitochondrial network recon-
structions. Our model describes the metabolism of 26
fatty acids and the biosynthesis of important phospho-
lipids such as cardiolipin, phosphatidylserine and phos-
phatidylcholine. Furthermore, the amino acid metabolism
is included to greater extent such as the synthesis of non-
essential amino acids (e.g. glycine) which is not part of the
mitochondrial networks.
Finally, we compared CardioNet to a genome-scale
reconstruction of the human heart [25]. Although the
fatty acid metabolism is represented in the human heart
model to a greater extent compared to the mitochon-
drial networks [23,24], important phospholipids such as
cardiolipin and the cholesterol biosynthesis in the perox-
isome are missing. We found no localisation of citric acid
cycle compounds in the mitochondrion such as fumarate
and succinate which only occur in the cytosol. More-
over, we applied the presented physiological functions of
the cardiomyocyte as part of the network reconstruction
process (see Additional ﬁle 6) to test the partial network
of the human heart [25]. From 110 tested functions 53
had no feasible solution, this included important cellu-
lar functions such as the citric acid cycle. Our ﬁndings
are in concordance with previous studies showing that
automatisied network reconstructions based on Recon1
not necessarily lead to a functional network [4,68].
Calculation of substrate and oxygen uptake rates for ATP
consumption in varied substrate availability
We analysed the eﬃciency of cardiac metabolism in
altered substrate supply by applying the metabolic net-
work. The dephosphorylation of ATP through myosin
light chain kinase is an important step in the cross-
bridge cycle to generate cardiac contraction [56,57]. This
dynamic process is not described in the metabolic net-
work. Therefore we demanded a baseline ATP consump-
tion rate (vATPase) of 21.6 mmol · min−1 · (l cell)−1 [69] to
include this important function of the cardiomyocyte.
The target function (vt) for these simulations reads as
following:
vt = vATPase (1)
Oxidation of available substrates m should provide suf-
ﬁcient ATP synthesis to enable this ATP consumption rate
(vATPase). We chose glucose, oleate, acetoacetate and lac-
tate as alternative energy-delivering substrates, that can be
taken up and oxidized by cardiomyocytes to generate ATP.
The external uptake rate for each substrate is expressed by
vm (m = 1, 2, ..., ns) and were described as following:
vm = (βm · vs) (2)
where the coeﬃcient β (0 ≤ βm ≤ 1) denotes the relative
share of the respective substrate m in the total substrate
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Table 2 Metabolic and physiological functions tested for themetabolic network
Classiﬁcation Metabolic function Cellular function Reference
1. Carbohydrates
• Monosaccharides Glucose and fructose metabolism Energy production [28,29]
Glycogen formation short-term energy storage [22]
Ribose Energy production [30,31]
Formation of ribonucleotides
2. Carboxylic acids Degradation of ketone bodies Energy production during fasting [32,33]
and diabetes
3. Lipids
• Cholesterol De novo synthesis (cytosol, peroxisome) Membrane synthesis [34,35]
• Fatty acids Formation of (semi)-essential fatty acids Membrane synthesis [36,37]
β-oxidation of (non)-essential fatty acids Energy production [38-40]
• Triacylglycerides De novo synthesis/ degradation of Mono-, Membrane synthesis [41,42]
Di- and Triacylglycerides








• Sphingolipids Ceramides Membrane formation, apoptosis [46]
4. Proteins
• Amino acids Formation of (non)-essential amino acids Precursors of cellular proteins, nucleic acids, [47,48]
glutathione and thioredoxin
Degradation of (non)-essential amino acids Amino acid homoeostasis, [49]
anaplerotic reactions of TCA cycle
Glutamine formation Ammonia detoxiﬁcation, Protein [50]
de novo synthesis
De novo synthesis of L-Carnitine Transport of fatty acids from cytosol into [51,52]
mitochondria during β-oxidation
• Tripeptide De novo synthesis of Glutathione Prevention of cellular damage due to ROS [53]
• Polyamines Formation/ degradation of Prutescine and Spermidine Cell growth and division [54,55]
• Proteins De novo synthesis of:
Myosin, Titin, α-Sarcoglycan, Tropomyosin, Troponin T Contractile apparatus, enabling muscular contraction [56,57]
De novo synthesis of Thioredoxin Prevention of cellular damage due to ROS [47,48]
5. Nucleic acids
• Nucleobases De novo synthesis/ degradation of purine Precursors of nucleosides, deoxy-ribonulceotides [58,59]
and pyrimidine nucleotides and ribonucleotides
Salvage of purine and pyrimidine nucleotides Maintaining energy state [60]
De novo synthesis/ rephosphorylation of:
◦ nucleosides (ATP, CTP, GTP, TTP, UTP) Energy production for muscular contraction [59,61-63]
◦ NADH, NADPH Energy production and providing redox-state [64,65]
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uptake ﬂux vs (see Methods). We modiﬁed the coeﬃcient
β on a ﬁne grid of values between 0 and 1 and per-
formed in total 176851 ﬂux minimization computations,
while minimizing the sum of external uptake ﬂuxes with-
out restricting the oxygen supply (see Additional ﬁle 7
for constraints; Additional ﬁle 8 and 9 for predicted ﬂux
values).
The demanded ATP consumption rate could be
achieved with each simulated substrate composition for
glucose, oleate, acetoacetate and lactate. Nonetheless oxy-
gen and substrate demands diﬀered clearly between sub-
strate combinations as presented in Figure 1. A minimal
oxygen requirement for all simulations was vO2 = 3.6007
mmol · min−1 · (l cell)−1 and only reached in exclusive
utilization of glucose, as can be seen in Table 3 and
Figure 2A. Simulating exclusive utilization of oleate
resulted with an increased oxygen uptake to a max-
imum of vO2 = 4.1101 mmol · min−1 · (l cell)−1, while
only a minimal total substrate uptake rate was required
(vs = 0.162 mmol · min−1 · (l cell)−1). To identify opti-
mal substrate compositions, we used the oxygen and
total substrate uptake rate as criteria. As illustrated in
Figure 2A, we calculated for each simulation a euclidean
based measure (Ci+ ,see Methods) and evaluated the dif-
ference between actual oxygen and total substrate demand
to the best and worst achieved values. The optimal sub-
strate composition should satisfy the metabolic target
function, while requiring as little oxygen and substrates as
possible.
In the extreme situation that only one substrate is
exclusively oxidized, glucose and oleate were almost iden-
tical optimal in terms of oxygen and total substrate
demand according to our selected eﬃciencymeasure (Ci+ ;
Table 3, Figure 2A). Simulating more physiological sit-
uations in which all four substrates could be utilized,
we determined an oleate and glucose percentage of 21%
Figure 1 Illustration of total substrate uptake rate (vs) and oxygen demand (vO2 ) for a ﬁxed glucose supply with (A) β = 0.25 and (B)
β = 0.75. The ATP consumption rate (vATPase) were restricted to 21.6 [ mmolmin·(l cell) ]. The panels A.1 and B.1 refer to the oxygen demand (vO2 ) for the
given glucose proportion, while panels A.2 and B.2 refer to the total substrate uptake rate (vs). For each panel we marked the optimal substrate
composition (*): (A) vGlucose=25%, vOleate=64%, vAcetoacetate=0%, vLactate=11%, (B) vGlucose=75%, vOleate=25%, vAcetoacetate=0%, vLactate=0%.
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Table 3 Simulation of varied substrate availability: baseline ATP consumption
βGlucose βOleate βAcetoacetate βLactate vO2 vs Ci+
[ mmolmin·(l cell) ] [
mmol
min·(l cell) ]
0.00 1.00 0.00 0.00 4.1101 0.1626 0.6849
1.00 0.00 0.00 0.00 3.6007 0.6005 0.6576
0.00 0.00 1.00 0.00 3.9269 0.9806 0.2791
0.00 0.00 0.00 1.00 3.8124 1.2701 0.2091
0.79 0.21 0.00 0.00 3.8534 0.3823 0.7334
0.42 0.37 0.09 0.12 3.9830 0.3154 0.7000
0.33 0.19 0.43 0.05 3.9420 0.4536 0.6500
0.20 0.16 0.26 0.38 3.9485 0.5292 0.6000
0.46 0.03 0.46 0.05 3.7757 0.6847 0.5500
0.17 0.09 0.01 0.73 3.8880 0.7020 0.5000
0.20 0.04 0.41 0.35 3.8534 0.7841 0.4500
0.16 0.03 0.33 0.48 3.8448 0.8575 0.4000
0.06 0.05 0.03 0.86 3.8794 0.8942 0.3600
0.02 0.02 0.52 0.44 3.9010 0.9677 0.3000
0.07 0.00 0.07 0.86 3.7930 1.1556 0.2500
0.00 0.00 0.13 0.87 3.8297 1.2247 0.2070
All data is ranked by the calculated eﬃciency in descending order and given fully for exclusive utilization of each substrate. Results for altered substrate availability are
listed by the achieved eﬃciency with a value of: 0.25, 0.3,0.36, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65 and 0.7. A substrate combination of 79% glucose and 21% oleate to the total
substrate uptake rate attained the highest calculated eﬃciency (Ci+ =0.7334). Least eﬃcient (Ci+ =0.2070) was a combination of 13% acetoacetate and 87% lactate. For
a complete overview of all results, please see Additional ﬁle 8 and 9. vO2 indicates oxygen demand; vs, total substrate uptake rate; and Ci+ , calculated eﬃciency.
and 79%, respectively, most optimal (Ci+=0.7334; see
Table 3). In contrast predominate utilization of lactate
showed to be least optimal. Especially sole lactate uti-
lization required a maximal total substrate uptake rate
of vs = 1.2701 mmol · min−1 · (l cell)−1, thus 7.84-fold
higher than in case of oleate utilization. We determined
the lowest eﬃciency for a total substrate combination
of 13% acetoacetate and 87% lactate (Ci+ = 0.2070, see
Table 3).
To identify alternate ﬂux solutions that can equally sat-
isfy the problem, i.e. yield the same optimal solution,
we performed additional simulations (see Methods). The
optimization problem was repeated for substrate combi-
nations with the highest and lowest calculated eﬃciency
(see Table 3). We determined 4 alternative distributions
yielding the same optimal solution for the substrate com-
bination achieving the highest calculated eﬃcency (79%
oleate, 21% glucose). The calculated distributions showed
no signiﬁcant diﬀerence from the original distribution
(F=135, Pr(>F)<2e-16, p≤0.001) and 90.70% of the ﬂuxes
were unique, thus the variance (s) equal to zero (see
Additional ﬁle 10).
Furthermore, 11 alternative distributions were identi-
ﬁed for the least optimal substrate combination show-
ing no signiﬁcant diﬀerence from the original distri-
bution (F=135, Pr(>F) <2e-16, p≤0.001) and 74.41%
unique ﬂux solutions (s=0). The largest variance (s=0.24)
was found for ﬂux rates of creatine and phospho-
creatine transport into the mitochondrion as well as
cytosolic and mitochondrial creatine kinase. However,
we found all ﬂuxes representing the external substrate
and oxygen uptake with unique solutions (see Additional
ﬁle 10).
Validation of calculated eﬃciency
To validate our results, we simulated substrate compo-
sitions as determined in a recent experimental study
[70], which investigated the utilization of glucose, lactate,
oleate, acetate and ketone bodies (acetoacetate, (R)-3-
hydroxybutanoate) in dependence of workload and insulin
to improve the perfusion system for the isolated rat heart.
We performed simulations with substrate compositions
as present in the experiments and determined ﬂux distri-
butions while assuming again a baseline ATP consump-
tion rate (vATPase) of 21.6 mmol · min−1 · (l cell)−1 [69].
The results, summarized in Table 4 and Figure 2B, show
that calculated ﬂux rates are in good concordance with
experimentally determined uptake rates and correspond
in many cases. The oxygen demand is underestimated in
all simulations compared to the experiment but in sole
acetate oxidation.
Moreover, the total substrate uptake rate is increased
in simulations for sole utilization of acetoacetate and
in combined utilization of acetate and glucose. Here,
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Figure 2 Calculation of eﬃciency measure. A. Illustration of
oxygen (vO2 ) and total substrate uptake rates (vs) for exclusive
utilization of glucose (), oleate (+), acetoacetate (•) and lactate ().
Calculated distances for each criterion were visualized for
acetoacetate, with dotted lines indicating distances to minimal and
maximal oxygen uptake rate and straight lines to respective minimal
and maximal total substrate uptake rates. Additional markers indicate
theoretical values for best (green circle) and worst (red circle)
solution. The eﬃciency index Ci+ is deﬁned as the relative distance for
each solution to the best-case solution: Ci+ = Si−Si+ +Si− . B. Bar plots for
comparison of calculated eﬃciency indices for simulated substrate
compositions to experimental results [70].
the ratio of calculated oxygen demand to total substrate
uptake rate shows the greatest deviance to experimen-
tally obtained values. To further compare our simulations
with the experiment, we determined for each substrate
composition eﬃciency measures as described above. As
depicted in Figure 2B, the calculated eﬃciency indices
were almost identical except for simulations of lactate oxi-
dation. Here, the required oxygen and substrate demand
to satisfy the baseline ATP consumption rate obtained a
more favourable relation as the calculated oxygen demand
in sole oleate utization was clearly underestimated. Fur-
thermore, the oxygen and substrate demand increased to
a maximum (Ci+ = 0, see Table 4, Figure 2B) in simula-
tions of sole acetate utilization. This explains diﬀerences
between calculated eﬃciency indices. In agreement with
our simulations, oxidation of glucose and oleate showed
to be more optimal in terms of oxygen demand and total
substrate uptake rate.
The comparison of experimental results in oxidation
of acetoacetate with our simulations are limited, due to
reduced cardiac work during the perfusion experiment
and altered substrate application. Our simulations con-
sider direct presence of acetoacetate and glucose, while in
the experiment glucose was added at a later time in the
perfusion. The data, summarized in Table 4, shows that
sole utilization of acetoacetate is less eﬃcient than glucose
or oleate oxidation, but seems to achieve more favourable
oxygen and substrate uptake rates than acetate and lactate.
Calculation of substrate and oxygen uptake rates for
satisfying a cardiomyocyte target function in varied
substrate availability
Cardiomyocytes have to maintain an adequate ATP syn-
thesis together with a multitude of metabolic functions
including abundance of contractile proteins, membrane
integrity and protection against reactive oxygen species.
To reﬂect these metabolic functions, we extended the
metabolic target function (vt) by including the production
of NADPH besides ATP and important membrane lipids:
ceramide (cer), cardiolipin (cl), phosphatidylcholine (pc),
phosphatidylethanolamine (pe) and sphingomyelin (sm).
vt = vATPase + vcer + vcl + vpc + vpe + vsm (3)
The corresponding metabolic ﬂux rates were obtained
from experimentally determined synthesis rates of mem-
brane lipids from tracer studies [71,72]. We demanded
for each phospholipid species speciﬁc ﬂux rates with
respect to reported fatty acid composition of membrane
lipids from human heart tissue [73,74]. All experimen-
tal ﬂux rates were referred to a single cardiomyocyte cell
volume of 2.16e-11 l (see Methods, Additional ﬁle 7). Tak-
ing into account possible short-term storage of energy,
we allowed the synthesis of glycogen during simulations
while restricting the glycogenolysis to a maximal rate as
determined in previous investigations [75].
The myocardial defending mechanisms against hypoxia
are mostly represented by NADPH to maintain reduced
glutathione. To consider this aspect, we performed an
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Table 4 Simulation of experimental substrate supply and comparison by calculated eﬃciencyCi+
Simulation Experiment
Exp. Substrate β m vO2 vs vO2/vs Ci+ vO2 vs vO2/vs Ci+
[ mmolmin·(l cell) ] [
mmol





1 Glucose 1.00 3.60 0.60 6.00 0.83 4.28 0.55 7.84 0.78
2.1 Lactate 1.00 3.81 1.17 3.25 0.60 4.71 1.41 3.34 0.21
2.2
Glucose 0.23
3.73 0.96 3.89 0.69 4.70 1.59 2.96 0.15
Lactate 0.77
3.1 Oleate 1.00 4.11 0.16 25.37 0.82 4.94 0.18 28.07 0.67
3.2
Glucose 0.54
4.02 0.24 16.75 0.85 4.36 0.21 20.57 0.91
Oleate 0.46
4.1 Acetate 1.00 4.8 2.4 2 0 4.28 1.68 2.55 0.31
4.2
Glucose 0.05
4.6 2.11 2.19 0.14 4.69 1.46 3.21 0.2
Acetate 0.95
5.1 Acetoacetate 1.00 3.93 0.98 4.00 0.65 4.20 0.53 7.89 0.59
5.2
Glucose 0.26
3.81 0.86 4.41 0.71 4.95 1.01 4.91 0.37
Acetoacetate 0.74
vO2 indicates oxygen demand;vs, total substrate uptake rate; Ci+ , calculated eﬃciency.
initial simulation to determine the basal NADPH forma-
tion in case of unrestricted substrate supply. We deter-
mined a rate of 2.13e-05 mmol · min−1 · (l cell)−1 and
3.05e-03 mmol · min−1 · (l cell)−1 for the cytosolic and
microsomal glucose-6-phosphate dehydrogenase, while
no ﬂux was found for the NADPH producing isocitrate
dehydrogenase. The rate of cytosolic glucose-6-phosphate
dehydrogenase corresponded to 0.08% of the hexokinase
ﬂux rate distribution. We found an overall NADPH pro-
duction rate of 1.42e-05 mmol · min−1 · (l cell)−1 which
was included into the simulations as a minimal required
rate of NADPH synthesis in addition to the metabolic
target function.
In total we performed 218618 simulations of the altered
supply of 9 diﬀerent substrates (ns=9). As expected, no
solutions were found in case of absent alpha-linoleate
and docosahexaenoate supply, thus these fatty acids are
required as a precursor for the biosynthesis of certain
phospholipid species in themetabolic network and cannot
be replaced by any other substrate [76].
To identify optimal substrate combinations, we cal-
culated for each simulation the eﬃciency index (Ci+ )
based on three criteria: (i) oxygen demand (vO2), (ii)
total substrate uptake rate (vs) and (iii) endogenous
glucose derived from glycogen turnover (vGL). We iden-
tiﬁed high eﬃciency indices for substrate combinations
with a major share of fatty acids and glucose, as pre-
sented in Table 5. Especially a substrate combination
of 90% Glucose, 5% of palmitate and 1.667% of alpha-
linoleate, eicosapentaenoate and docosahexaenoate
showed to be more favourable than any other substrate
combination (vO2 = 6.9154 mmol · min−1 · (l cell)−1;
vs = 4.8859 mmol · min−1 · (l cell)−1 ; Ci+=0.8438). As
expected, the eﬃciency (Ci+ ) were directly propor-
tional to increasing share of glucose and fatty acids
(Figure 3A) and inversely proportional increasing share
of acetoacetate and lactate (Figure 3A). In fact, a sub-
strate combination of 95% acetoacetate and 5% fatty
acids with a share of 0.83% palmitate, 0.83% alpha-
linoleate and 3.33% docosahexaenoate resulted to be
least optimal to fulﬁl the demanded metabolic target
function (see Table 5). The oxygen demand achieved
a maximum (vO2 = 48.421 mmol · min−1 · (l cell)−1)

















Table 5 Simulations of substrate availability: cardiomyocyte target function
βGlucose βPalmitate βStearate βOleate βα−Linoleate βEPA βDHA βAcetoacetate βLactate vO2 vs vGL vGS Ci+







0.9000 0.0500 0.0000 0.0000 0.0167 0.0167 0.0167 0.0000 0.0000 6.9154 4.8859 0.0000 0.4027 0.8438
0.2500 0.0000 0.0000 0.0000 0.2083 0.0000 0.0417 0.0000 0.5000 4.0502 0.4093 0.1450 0.0000 0.8000
0.4500 0.0417 0.0000 0.0000 0.0417 0.0000 0.1667 0.3000 0.0000 11.4761 2.0466 0.0000 0.0000 0.7500
0.2500 0.0250 0.0000 0.0500 0.0250 0.0250 0.0250 0.5500 0.0500 14.9112 3.2573 0.0000 0.0690 0.7000
0.0000 0.0250 0.0000 0.0250 0.0250 0.0000 0.0750 0.1000 0.7500 17.3465 3.4111 0.0098 0.0000 0.6500
0.2500 0.0167 0.0167 0.0000 0.0167 0.0167 0.0333 0.6500 0.0000 20.2825 4.8859 0.0000 0.1150 0.6000
0.0500 0.0000 0.0333 0.0000 0.0167 0.0333 0.0167 0.4500 0.4000 22.5428 4.8859 0.0000 0.0103 0.5500
0.1500 0.0000 0.2250 0.0750 0.0750 0.0000 0.0750 0.1500 0.2500 25.2571 10.2332 0.0000 0.4532 0.5000
0.4000 0.0000 0.0167 0.0000 0.0083 0.0083 0.0167 0.3500 0.2000 27.6323 9.7718 0.0000 0.3434 0.4500
0.3000 0.0000 0.0000 0.0083 0.0083 0.0000 0.0333 0.0500 0.6000 29.8822 10.2332 0.0000 0.2629 0.4000
0.2500 0.0167 0.0083 0.0000 0.0083 0.0000 0.0167 0.3000 0.4000 32.3227 10.2332 0.0000 0.2266 0.3500
0.2500 0.0083 0.0083 0.0000 0.0083 0.0000 0.0250 0.5000 0.2000 34.8810 10.2332 0.0000 0.2266 0.3000
0.2000 0.0000 0.0250 0.0000 0.0083 0.0083 0.0083 0.7500 0.0000 37.2907 9.7718 0.0000 0.1757 0.2500
0.0000 0.0000 0.0083 0.0083 0.0083 0.0083 0.0167 0.3000 0.6500 38.8292 9.7718 0.2160 0.0000 0.2000
0.0000 0.0083 0.0083 0.0083 0.0083 0.0000 0.0167 0.4000 0.5500 41.2341 10.2332 0.2160 0.0000 0.1500
0.0000 0.0167 0.0000 0.0000 0.0083 0.0167 0.0083 0.9500 0.0000 44.3334 9.7718 0.0000 0.0029 0.1000
0.0000 0.0000 0.0083 0.0000 0.0083 0.0000 0.0333 0.9000 0.0500 47.5569 10.2332 0.0120 0.0000 0.0500
0.0000 0.0083 0.0000 0.0000 0.0083 0.0000 0.0333 0.9500 0.0000 47.9063 10.2332 0.2160 0.0000 0.0100
Results are shown for simulations of varied substrate availability of glucose, acetoactate, lactate and 6 diﬀerent fatty aicids: palmitate, stearate, oleate, alpha-linoleate, eicosapentaenoate and docosahexaenoate. For each
simulated composition eﬃciency values Ci+ were calculated based on three criteria qj (j=1,2,...,nj): (1) oxygen requirement (vO2 , q1) , (2) total substrate uptake rate (vs, q2) and (3) endogenous glucose dervied from
glycogenolysis (vGL, q3). Results are ranked by the calculated eﬃciency Ci+ in descending order and given for maximal and minimal calculated eﬃciency values. Further results are shown for each eﬃciency value of 0.3, 0.35,
0.4, 0.45, 0.5, 0.55, 0.6, 0.65. Rates for oxygen requirement (vO2 ), total substrate uptake rates (vs), glycogenolysis (vGL) and glycogen synthesis (vGS) are given in mmol ·min-1 · (l cell)-1. For a complete overview of all results,
please see Additional ﬁle 11 and 12. GL indicates glycogenolysis; GS, glycogen synthesis; EPA, eicosapentaenoate; and DHA, docosahexaenoate.
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Figure 3 Calculation of substrate and oxygen uptake rates in varied substrate availability. A. Calculated eﬃcency values for each substrate in
varied share (βm) of the total substrate uptake rate (vt ). Values are mean ± standard deviation. B. Box and whisker plots of the proportion of
substrates according to the total substrate uptake ﬂux by eﬃciency score Ci+ greater than 0.8. The bold horizontal line in panels indicate mean.
Ci+ ≥ 0.8: n = 76925. ° Outliers.
supplemented by oleate (0.83%), alpha-linoleate (0.83%)
and docosahexaenoate (3.33%), while a combination
of acetoacetate (45%), lactate (35%), glucose (15%),
oleate (1.67%), alpha-linoleate (0.8%) and docosahex-
aenoate (2.5%) required a maximal total substrate supply
(vs = 10.2332 mmol · min−1 · (l cell)−1, see Additional
ﬁle 11 and 12).
Again we repeated the optimization problem to identify
alternative ﬂux solutions (see Methods) in substrate com-
binations with the highest and lowest calculated eﬃciency
(see Table 5). Here, we identiﬁed 202 alternative distri-
butions with 71.92% unique ﬂux solutions (variance s=0)
achieving the same objective for the substrate combina-
tion with the highest calculated eﬃciency (see Additional
ﬁle 10). The alternative distributions were without sig-
niﬁcant diﬀerence from the original distribution (F=462,
Pr(>F) <2e-16, p≤0.001).
Similar, 216 alternative distributions with 56.96%
unique ﬂux solutions were found for the substrate
combination with lowest calculated eﬃciency. The
calculated distributions showed no signiﬁcant diﬀerence
from the original distribution (F=278, Pr(>F) <2e-16,
p≤0.001). The largest variance (s=29.83) was again found
for ﬂux rates of creatine and phosphocreatine transport
into the mitochondrion as well as cytosolic and mito-
chondrial creatine kinase. In addition we found variability
for beta-oxidation of fatty acids and ATP:nucleoside-
diphoshate phosphotransferase. Each ﬂux representing
the glycogenolysis, external substrate and oxygen uptake
was found unique (s=0) in all simulations (see Additional
ﬁle 10).
The data, as illustrated in Figure 3B, shows that the
variability of substrate combinations with a large eﬃ-
ciency index (Ci+ ≥0.8) increased with the advanced
objective function. The mean share (βx¯) of glucose,
fatty acids, acetoactetate and lactate where 0.231, 0.311,
0.221, and 0.237, respectively. The data, summarized in
Figure 3A, show for all fatty acids a similar pattern of cal-
culated eﬃciency. Nonetheless, the contribution to ATP
production diﬀered between saturated, monounsaturated
Karlsta¨dt et al. BMC Systems Biology 2012, 6:114 Page 11 of 20
http://www.biomedcentral.com/1752-0509/6/114
and polyunsaturated fatty acids. The mean rates for fatty
acid utilization and rates of ATP produced by fatty acid
utilization are summarized in Figure 4. Rates of ATP pro-
duced by beta-oxidation were calculated by assuming 120,
136, 134, 132, 142 and 156 moles of ATP derived from full
oxidation of palmitate, stearate, oleate, alpha-linoleate,
eicosapentaenoate and docosahexaenoate, respectively.
The vast majority of palmitate, stearate and oleate con-
tributed to phospholipid biosynthesis, while polyunsatu-
rated fatty acids were mostly degraded via beta-oxidation.
As illustrated in Figure 4A, alpha-linoleate was not
degraded by beta-oxidation, thus contributed fully to
phospholipid biosynthesis. In addition, we foundmaximal
ATP production through beta-oxidation in degradation
of docosahexaenoate and eicosapentaenoate (Figure 4B).
In fact, up to 99.1% and 98.82% of utilized docosahex-
aenoate and eicosapentaenoate could contribute to ATP
production, respectively.
Glycogenolysis and glycogen synthesis occurred
simultaneously throughout the simulations. In case
of excessive glucose supply, which was not needed to
fulﬁll the target function, glycogen was synthesized
with a maximal rate of 0.887 mmol · min−1 · (l cell)−1.
Figure 4 Exogenous utilization of fatty acids and ATP
production. A. Exogenous utilization of fatty acids and contribution
to ATP production by fatty acid beta-oxidation. B. Steady state rates
of ATP production from fatty acid beta-oxidation. Data are expressed
as boxplots.
Rates of exogenous glucose entering glycolysis were
signiﬁcantly greater than those from endogenous glyco-
gen degradation (Figure 5A; p≤0.05). Following this,
a large proportion of exogenous glucose was oxidized
by oxidative phosphorylation and was also signiﬁcantly
greater than those from endogenous glycogen degra-
dation (vexo = 0.437 ± 0.766 mmol · min−1 · (l cell)−1;
vendo = 0.091 ± 0.189 mmol · min−1 · (l cell)−1 ; p≤0.05).
In fact oxidative phosphorylation contributed the most to
cellular ATP production from exogenous and endogenous
glucose utilization (Figure 5B), with glycogen accounting
for 34.41% of ATP production (when glucose accounted
for 50% of the total substrate uptake rate). The per-
centage of ATP production deriving from endogenous
glucose oxidation by oxidative phosphorylation increased
to 80.16% in a glucose share less than 10% of the total
substrate uptake rate. These results are supported by
previous ﬁndings [77] showing a contribution of glycogen
to 41% of the total ATP production under experimental
conditions. In summary, the present results demonstrate
that an optimal metabolic and physiological function
of the cardiomyocyte is provided by utilization of long-
chain unsaturated fatty acids, supplemented by saturated
fatty acids polyunsaturated fatty acids, and exogenous
glucose.
Figure 5 Glucose utilization and ATP production. A. Degradation
of exogenous and endogenous glucose (glycogenolysis) by glycolysis
and oxidative phosphorylation. B. Steady state rates of aerobic and
anaerobic ATP production from glucose utilization derived from
exogenous glucose and glycogenolysis. Data are expressed as
boxplots. ∗ signiﬁcant diﬀerence between endogenous and
exogenous glucose. p<0.05 (unpaired t-test).
Karlsta¨dt et al. BMC Systems Biology 2012, 6:114 Page 12 of 20
http://www.biomedcentral.com/1752-0509/6/114
Discussion
In this study, we developed a comprehensive reconstruc-
tion of a system-scale stoichiometric model of a human
cardiomyocyte that accomplish a large set of metabolic
and physiological functions to study the metabolism of
cardiomyocytes. The model is based on previous human
network reconstructions [2-4] and a comprehensive inte-
gration of gene expression and further available exper-
imental evidence for metabolic reactions reported for
cardiomyocytes. Using ﬂux-balance analysis we ensured
the capability of the network to achieve a wide range
of metabolic target reactions required for maintaining
the structural and functional integrity of the cell [5,78].
The consistency and functionality of CardioNet is a clear
advantage compared to a previous automatisied genome-
scale network reconstruction of the human heart [25]
which lacks functionality.
CardioNet considers additional 228mitochondrial reac-
tions compared to two previously reported mitochondrial
networks of the human cardiomyocyte [23,24]. Especially,
the metabolism of 26 distinct fatty acids is included to
a greater extent with consideration of variable acyl-chain
composition of important phospholipids such as cardi-
olipin, phosphatidylserine and phosphatidylcholine. The
present reconstruction may serve as a reliable basis for the
integration and analysis of diﬀerent types of data to study
important metabolic processes of the human cardiomy-
ocyte. The estimation of ﬂux rates from tracer kinetic
data [79,80] or prediction of ﬂux changes inferred from
changes in gene expression level of metabolic enzymes
[81] under pathological conditions are only a few exam-
ples of possible applications.
Under physiological conditions cardiomyocytes are
metabolizing a wide range of substrates including fatty
acids, glucose, lactate, pyruvate, ketone bodies and amino
acids, to meet the ATP demand for muscle contraction
and further cellular mechanisms [9]. The rate of substrate
utilization is dependent upon (i) substrate availability, (ii)
requirement of ATP production for maintenance of car-
diac contraction, (iii) oxygen supply and (iv) hormonal
level of various hormones directly inﬂuencing substrate
uptake, e.g. insulin. Recent investigations in other cells
showed the importance of maximization of molar yield of
metabolites in order to maintain cellular integrity under
varied extracellular conditions [82]. In our study, we took
up this point and questioned how variations in the relative
proportions of glucose, lactate, fatty acids and ketone bod-
ies may inﬂuence the eﬃciency of cardiac metabolism. To
address this question, we applied the principle of ﬂuxmin-
imization [5] to enable the formation of deﬁned metabolic
targets while utilizing substrates in varied proportions. By
calculating a euclidean based-distance measure, we were
able to identify optimal substrate combinations to main-
tain cardiac contraction based on the criteria: (i) oxygen
demand, (ii) total substrate uptake rate and (iii) rate of
endogenous glucose derived from glycogenolysis.
As shown in the present study, a predominant oxida-
tion of fatty acids (79%) supplemented by glucose (21%)
showed to maintain most eﬃciently the required ATP
production. We found that in sole oleate utilization total
substrate requirement and oxygen consumption are more
favourable compared to glucose, lactate and acetoacetate.
Furthermore, predominant utilization of lactate and ace-
toacetate was least optimal to maintain ATP production.
These ﬁndings are supported by previous studies [70,83]
documenting reduced cardiac performances in predomi-
nately supply of ketone bodies. In diabetic conditions with
increased concentration of ketone bodies cardiac activity
improved with additional fatty acid supply indicating the
inadequacy of ketone bodies to eﬃciently maintain ATP
production.
To further validate our results, we simulated substrate
proportions as present in a previous study of the isolated
working rat heart [70] and compared the calculated eﬃ-
ciency measures derived from experimental values with
our simulations. We found the same ranking for eﬃ-
ciency of utilized substrates during simulations as in
the experimental study. During the experiment, cardiac
performance declined in a sole ketogenic environment
(acetoacetate, (R)-3-hydroxybutanoate) while a mixture of
glucose and acetoactetate seemed to reverse this eﬀect.
We calculated similar eﬃciency measures for ketone
body utilization during simulations and with experimen-
tal values, supporting these previous ﬁndings. In addition,
acetate showed the worst relation of oxygen demand to
total substrate requirement to fulﬁl the metabolic target,
both in results from simulations and experimental values.
Nonetheless, no decline in cardiac performance during
the actual experiment has been reported. In contrast to
our results, lactate were less eﬃcient during the experi-
mental setting as our simulations would have suggested.
These diﬀerences may be caused by substrate interac-
tions which cannot be considered by FBA simulations,
the reduced metabolic target function to ATP production
without consideration of any other metabolic function
and possibly observational error in the experiment.
On the basis of these results, we expanded the
metabolic target function by demanding besides ATP
the production of NADPH and the important mem-
brane lipids: ceramide, cardiolipin, phosphatidylcholine,
phosphatidylethanolamine and sphingomyelin. For this
purpose, we further modiﬁed the fraction of fatty acids
in the set of importable substrates by saturated (palmi-
tate, stearate), monounsaturated (oleate), long chain
poly-unsaturated omega-6 (alpha-linoleate) and omega-3
(eicosapentaenoic acid, doxosahexanoic acid) fatty acids.
Although long chain poly-unsaturated fatty acids (PUFA)
predominately serve as membrane lipids [12,15,16], there
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is evidence for occurrence of Acyl-CoA dehydrogenase
9 (ACAD-9) in human cardiomyocytes [84]. ACAD-9
catalyses the initial step of mitochondrial fatty acid beta-
oxidation. Moreover, a previous study [85] could show
enzymatic activity for ACAD-9 with long-chain unsatu-
rated acyl-CoA as substrate (e.g.:C22:6-CoA). This is in
concordance with another study [86] measuring rates of
fatty acid beta-oxidation for palmitate and docosahex-
aenoate. Hence, it is reasonable to consider fatty acid
beta-oxidation of PUFA for our simulations.
Demanding metabolic ﬂux rates as reported in pre-
vious experimental studies of membrane lipids [71,72]
and integrating the fatty acid composition of phospho-
lipids as reported by investigations in human heart tissue
[73,74], assured a physiological simulation of cardiomy-
ocyte metabolism. We further related each ﬂux rate to the
cellular volume of a single cardiomyocyte. Themyocardial
defence mechanisms against hypoxia are mostly eﬀected
by NADPH to maintain reduced glutathione. To con-
sider this aspect, we performed an initial simulation to
determine the basal NADPH formation by the glucose-
6-phosphate dehydrogenase, the rate limiting enzyme of
oxidative pentose phosphate pathway, in case of unre-
stricted substrate supply. This estimated basal rate of
NADPH production ( 1.42e-05 mmol · min−1 · (l cell)−1)
was demanded as minimal requirement in order to main-
tain cellular protection against ROS.
In addition, we considered cardiac short-term stor-
age of energy in particular glycogen, which could act
as a potential precursor for sn-glycerol, a known inter-
mediate for phospholipid biosynthesis, and ATP pro-
duction. During simulations we allowed the synthesis of
glycogen while including the limited amount of glyco-
gen storage by restricting glycogenolysis to a maximal
rate as determined in previous investigations [75]. As
shown, in the present study glycogen synthesis and
glycogenolysis occurred simultaneously throughout the
simulations, which is well in accordance with previ-
ous studies [75,77] documenting the same pattern. In
case the available glucose was not needed to fulﬁl
the metabolic target function, glycogen was synthesized
with a maximal rate of 0.887 mmol · min−1 · (l cell)−1.
The vast majority of utilized glucose during simulations
derived from exogenous uptake, indicating that endoge-
nous glycogenolysis was only utilized in a decreased
glucose supply. Both external and endogenous glucose
essentially contributed to ATP production by oxidative
phosphorylation.
Previously, Henning et. al. [77] demonstrated that glyco-
gen accounted for 41% of synthesized ATP in predom-
inately glucose oxidation. In agreement with this study,
our results show a glycogen contribution to ATP syn-
thesis from glucose oxidation which is dependent on
exogenous glucose supply. In case glucose accounts for
50% of the total substrate uptake rate, we found 34.41%
of ATP production from oxidative phosphorylation is
related to glycogen. Consequently with decreased glu-
cose supply to 25% of the total substrate uptake rate,
we found an increased contribution of glycogen up to
80.16%.
In order to test the robustness of our solutions we anal-
ysed the uniqueness of calculated ﬂux solutions. Depend-
ing on the complexity of the target function we found up
to 90.70% ﬂuxes with unique solutions which included ﬂux
rates for glycogenolysis and external substrate and oxygen
uptake for every tested substrate combination. Although
a certain amount of ﬂux solutions showed variability
none of the alternative distributions showed signiﬁcant
diﬀerence from the original distribution. The eﬃcency
analysis of substrate combinations is not compromised
by this small varibility and based on ﬂuxes with unique
solutions.
To our knowledge this is the ﬁrst study investigating
the eﬃciency of a large set of substrates, including long-
chain fatty acids, through simulation.We found utilization
of substrate combinations with a mixture of all investi-
gated substrate more eﬃcient compared to sole utilization
of single substrates. Here predominant utilization of fatty
acids (βm¯=0.311), especially long-chain unsaturated fatty
acids, supplemented by glucose (βm¯=0.231), acetoacetate
(βm¯=0.221) and lactate (βm¯=0.237) seemed to be more
favourable with the extended metabolic target function
which is in good concordance with our previous ﬁnd-
ings. Moreover, utilization of predominantly saturated
and C18 polyunsaturated fatty acids seemed to be more
favourable, than a greater share of long chain omega-3
poly-unsaturated fatty acids. This is supported by a recent
study [87] in isolated muscle ﬁbres from diabetic hearts,
where an increase of mitochondrial uncoupling was mea-
sured during exposure to fatty acid. The induced ROS
production in cardiomyocyte mitochondria led to activa-
tion of multiple adaptive mechanisms by which oxidative
damage can be prevented. The ambivalent role of long
chain omega-3 poly-unsaturated fatty acids is supported
by ﬁndings from other studies [15,16], that showed ben-
eﬁcial metabolic eﬀects in myocardial protection against
oxidative damage by incorporation of long chain omega-
3 poly-unsaturated fatty acids into mitochondrial mem-
brane phospholipids such as cardiolipin.
Our results indicate, that a switch from fatty acid utiliza-
tion to predominant glucose utilization in situations with
increased workload would not decrease the eﬃciency of
cardiac metabolism. This is indicated by a eﬃciency value
(Ci+=0.8438) for a combination of 90% glucose, 5% palmi-
tate, 1.67% alpha-linoleate, 1.67% eicosapentaenoate and
1.67% docosahexaenoate. During the simulations polyun-
saturated fatty acids contributed most to ATP production
via beta-oxidation, while the vast majority of palmitate,
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stearate and oleate were used for phospholipid biosyn-
thesis. In fact, up to 99.1% of utilized docosahexaenoate
and 98.82% of utilized eicosapentaenoate could contribute
to ATP production through degradation during beta-
oxidation, respectively. In addition, we found alpha-
linoleate did not undergo beta-oxidation, but served as
substrate in the biosynthesis of phospholipid. Consistent
with our previous ﬁndings, we found predominantly uti-
lization of acetoacetate least optimal with the extended
metabolic target function. Here, the oxygen demand and
mitochondrial oxygen consumption were greater than
with any other substrate combination, thus, possibly,
increasing the ﬂux through complex I of the mitochon-
drial oxidative phosphorylation which is considered a
main source of cellular ROS. Our observations suggest
that under metabolic conditions with increased acetoac-
etate levels (e.g. diabetes) cardiac contractility would be
aﬀected by decreased ATP formation and increased ROS
formation, which is linked to mitochondrial dysfunction
[18,19]. Nonetheless, it is beyond the scope of this study
to further analyse these mechanisms but our network
reconstruction might contribute to further investigation
by incorporation of gene expression level information of
metabolic enzymes mediated by PPAR.
Conclusions
In summary, our study provides a comprehensive, recon-
struction of the metabolic network of the human car-
diomyocyte (CardioNet) to study metabolic and physio-
logical functions of the cardiomyocyte.
The evaluation of metabolic eﬃciency in substrate sup-
ply and utilization necessitates consideration of oxygen
and substrate demand, as well as endogenous glucose
deriving from glycogenolysis. In aerobic conditions pre-
dominant utilization of saturated and long-chain unsat-
urated fatty acids supplemented by glucose proved to
be more favourable for eﬃcient cardiac metabolism
than utilization of acetoacetate or lactate. Furthermore,
we showed, that glycogenolysis and glycogen synthe-
sis occurred simultaneously. In conclusion, CardioNet




To identify a tissue speciﬁc set of metabolic reactions we
applied the algorithm by Shlomi et al. [6], which integrates
gene expression data with linear optimization problem.
The approach aims to ﬁnd a stationary ﬂux distribution
by maximizing the number of reactions whose activity
is consistent with their gene expression state [6]. We
obtained gene expression information in normal human
heart tissue samples from two diﬀerent datasets (GDS181
[88], GSE1145) which are available from Gene Expression
Omnibus [89]. A gene was considered to be expressed if
the expression value was equal or greater than a threshold
value of 100 or the Aﬀymetrix Call indicated a present
expression.
By using the Ensembl Homo sapiens database [90]
and KEGG orthology records [91], we mapped these
Aﬀymetrix probe set IDs to reactions of the global recon-
struction of the human metabolic network - Recon1 [2].
After applying the algorithm by Shlomi et al. [6] the result-
ing subnetwork comprised of 972 reactions and metabo-
lites for which corresponding reactions in KEGG were
identiﬁed based on the Enzyme Commission (EC) num-
ber. We extended this initial set of reactions by including
further KEGG reactions [91] associated with EC numbers
that are annotated as present in heart tissue by additional
databases such as the Braunschweig Enzyme database
(BRENDA) [92] and UniProtKB [93]. Further informa-
tion about metabolites not obtained from KEGG were
integrated by using the Human Metabolome Database
(HMDB) and Lipid Maps Classiﬁcation System [26] (see
Additional ﬁle 1).
Reactions were evaluated for tissue speciﬁcity and sub-
cellular localisation according to database knowledge and
reported experimental evidence from scientiﬁc literature.
We included reactions into the network if evidence were
found for occurrence in human cardiomyocytes or heart
tissue in general (e.g.: heart muscle, myocard, cardiac
tissue). In case no evidence were found for humans, we
relied on other mammalian species and human ortholo-
gous genes allowing inference of the reaction. Information
on transport reactions was obtained from the Trans-
port Classiﬁcation database [94], Reactome database [95]
and another metabolic network of the human hepatocyte
(HepatoNet1, [4]) providing a large set of manually
curated transport processes. We included transport pro-
cess from this study in case we found evidence for occur-
rence in human cardiomyocyte.
Each reaction in the network was assigned to one of
the following sub-cellular localisation: external, cytosol,
mitochondrion, lysosome, peroxisome and micro-
some. The compartments endoplasmic reticulum (ER),
Golgi apparatus and microsome are represented in the
metabolic network as one combined compartment,
microsome. Communication among endoplasmic retic-
ulum, Golgi apparatus and microsome is mediated by
vesicular transport processes which can be only inade-
quately included into the FBA methodology. In addition,
recent studies demonstrated the experimental diﬃculty
of proteomic proﬁling of the microsomes [96,97]. The
determination for sub-cellular localisation was based on
experimental evidence (protein localisation, targeting
sequences and subcellular fractionation) and indirect
physiological or biochemical evidence. In the absence
of information, reactions were assigned to the cytosolic
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compartment (see Additional ﬁle 1 and 5). The direc-
tionality of reactions were set according to Gibbs energy
(G) as obtained from a prediction method [98] (see
Additional ﬁle 2).
For the integration of diﬀerent level of information we
used the METANNOGEN software [99]. The complete
overview of present genes in the metabolic network is
provided in Additional ﬁle 13. The ﬁnal reconstructed
network is available in SBML format (see Additional
ﬁle 5).
Flux balance analysis
The network was subjected to further ﬂux-balance sim-
ulations with diﬀerent metabolic objectives to test func-
tionality (see Additional ﬁle 3). The optimization objective
has been the minimization of internal ﬂuxes [5]. We
deﬁned a set of exchangeable metabolites which were
applied as constraints in the optimization problem (see
Additional ﬁle 3). In addition to this, the reconstructed
network was subjected to functional pruning [78] by
reducing the model to a smaller sub-network which con-
tains no dead-ends or blocked reactions that may not
carry a non-zero ﬂux. For this purpose, we deﬁned a set
of exchangeable metabolites (see Additional ﬁle 3) used
for pruning based on metabolic and physiological func-
tion of the cardiomyocyte (see Table 2). This process
revealed (i) missing reactions, (ii) missing transporters
and (iii) incomplete reaction directionality which were
part of further curation process.
Calculating uptake rates of substrates and oxygen in varied
substrate supply
We used the metabolic network to assess the inﬂuence
of nutritional blood supply on the metabolic eﬃciency
of the cardiomyocyte to accomplish various metabolic
objectives. For this purpose, we deﬁned the metabolic
target vt as a linear combination of all those ﬂuxes vr
(r=1,2,...,nt), which have to be accomplished by the net-






The metabolic ﬂux rates vr were obtained from exper-
imentally determined synthesis rates which were taken
from previous investigations [69,71,72]. We further con-
sidered the variable fatty acid composition of phospho-
lipids as reported in human heart tissue [73,74]. The
detailed list of included synthesis rates is provided in the
Additional ﬁle (see Additional ﬁle 7). To simulate altered
substrate availability, we deﬁned the total substrate uptake
ﬂux (vs) as a linear combination of the external uptake
rates vm (m=1,2,...,ns) for each oxidized substrate n. The
substrate availability in the external space is reﬂected by
the coeﬃcient βm with
ns∑
m=1
βm = 1, 0 ≤ βm ≤ 1. (5)
The higher the share of substrate n in the external
medium, the higher its share in the total substrate uptake
space (vs). This assumption is justiﬁed by experiments
carried out with the perfused isolated heart [70] show-
ing the relation between measured uptake rates of various
energy-delivering substrates directly reﬂected the ratio
of these substrates in the perfusion medium. The result-
ing substrate uptake rate for each simulated substrate
composition i (i=1,2,...,ni) reads, as follows:
vmi = (βmi · vs). (6)
The optimization problem was described for accom-
plishing the metabolic target ﬂux (vt) while minimizing
the sum of the total substrate uptake rate (vs) and oxygen
uptake rate (vO2). The internal and exchange ﬂuxes of the
metabolic network were deﬁned as v and the stoichiomet-
ric matrix of the complete metabolic network as N. The
lower and upper bounds on ﬂuxes are expressed as vmin
and vmax.
The optimization problem according to the ﬂux-
minimization principle for each simulated substrate com-
position i reads, as follows:
minimize (vs + vO2) (7)
subject to N · v = 0, (8)





vm = (βm · vs). (11)
Alternate optima
Presumed the original problem is feasible and a value for
the objective can be calculated, the solution for v (see
equation (8)) is not necessarily unique. Multiple solutions
might occur to solve the problem and cause degeneration
of the ﬂux distribution. In order to identify alternate ﬂux
solutions that can equally satisfy the problem, i.e. yield the
same optimal solution, we performed additional simula-
tions. The MILP was re-solved after adding a constraint
(z∗) for a single ﬂux of the original ﬂux distribution which
was set to either 1.01-fold (z∗1) or 0.99-fold (z∗2) of its orig-
inal calculated ﬂux value (v0). We repeated this additional
constraining for one ﬂux after the other and resolved the
optimization problem.
z∗1 = 1.01 · v0, (12)
z∗2 = 0.99 · v0. (13)
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The modiﬁed optimization problem reads as follows:
minimize (vs + vO2) (14)
subject to N · v = 0, (15)





vm = (βm · vs) (18)
z∗1, z∗2. (19)
In case no feasible solution could be found, the respec-
tive original ﬂux solution is dependent on one or more
ﬁxed ﬂuxes of the target function and cannot be var-
ied. Each feasible solution yielding the same optimum as
the original was considered for further variance analy-
sis. In case the variance is equal to zero the respective
ﬂux is uniquely deﬁned. On the other hand, indicates
a non-zero ﬂux value an unequivocally deﬁnition of the
respective ﬂux. These ﬂuxes may vary without aﬀecting
the optimal behaviour of the metabolic network, based on
the capability of the network to compensate these varia-
tions.We repeated the optimization problem for substrate
combinations which were identiﬁed with the highest or
lowest eﬃciency value while satisfying (1) a baseline ATP
consumption rate and (2) a target function of the car-
diomyocyte ( see Additional ﬁle 10). Based on the variance
analysis for all four examples, we found no signiﬁcant dif-
ference between the solutions. About one third of the
ﬂuxes cannot be changed without violating the demanded
target function, thus leading to an infeasibility of the
problem.
Euclidean based distancemeasure for eﬃciency
To identify optimal substrate combinations within all sim-
ulations of altered substrate availability, we used as criteria
qj (j=1,2,...,nj): the oxygen demand (vO2 , q1), total sub-
strate uptake rate (vs, q2) and endogenous glucose derived
from glycogenolysis (vGL, q3). Optimal substrate com-
binations should not only meet a minimal distance to
the best achieved solution, but also a maximal distance
to the worst achieved solution for each criterion. This
takes into account, that one solution could show mini-
mal requirement of substrates while the oxygen demand
and glycogenlysis increases. Euclidean distances were
calculated for every simulated substrate composition i
(i=1,2,...,ni) by, ﬁrst, determine the best-case (q+j ) and
worst-case solution (q−j ) from all simulations for each
criterion as the minimal and maximal uptake rate, respec-
tively. Secondly, the distances between actual ﬂux rate (qji)













(qij − q−j )2 ∀ i = 1, ..., ni. (21)
The relative distance for each solution to the best-case
solution is deﬁned as the eﬃciency index Ci+ for the
considered substrate combination:
Ci+ = Si−Si+ + Si− (22)
with a maximal theoretical eﬃciency index Ci+ equal
to 1. Substrate compositions with the highest overall
match and eﬃciency indices Ci+ close to 1 were con-
sidered as optimal solutions for the chosen metabolic
objective.
Cardiomyocyte volume
We referred all ﬂux calculations to the volume of one
single cardiomyocyte to integrate experimental ﬂux rates
from diﬀerent studies (see Additional ﬁle 7). The car-
diomyocyte volume (Vmyo) was calculated as follows:
Vmyo = π4 · d2 · l, with a diameter (d) of 14 μm and length
(l) of 140 μm [100,101].
(Vmyo) = 2.16 e − 11 l. (23)
Computation
The computation was performed with the aid of CPLEX
10.1 (ILOG, Gentilly, France) and FASIMU [102].
Statistical analysis
Comparison of mean values between groups was evalu-
ated with unpaired t-test. A value of p < 0.05 was con-
sidered signiﬁcant. Statistical signiﬁcance between ﬂux
solutions for the analysis of alternate ﬂux solutions was
determined by use of 1-way ANOVA. Vertical lines in the
histograms indicate means ± SE.
Additional ﬁles
Additional ﬁle 1: Metabolites of the metabolic network.Metabolites
listed in this table occur in the metabolic network. For each entry a unique
network identiﬁer is given and provided with information of metabolite
title, title synonym, metabolite sum formula and assigned compartment.
Additionally cross-references to other databases are given and refer to the
following databases: UniProtKB (UniProtKB entry), KEGG (Compound ID),
Lipid Maps (LM ID), Pub Chem (CID) and Human Metabolome Database
(HMDB ID). Abbreviations used in the table for compartments are as
following, ext: external, cyto: cytosol, mito: mitochondrion, lyso: lysosome,
peroxy: peroxisome and micro: microsome.
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Additional ﬁle 2: References. During the network reconstruction
additional evidence for occurrence of metabolic reactions in the
cardiomyocyte were obtained from previously reported studies. This table
gives a full list of cross-references to PubMed identiﬁer (PMID) providing
evidence for included reactions of the metabolic network. Furthermore,
directionality of reactions was set according to Gibbs energy (G, kJ/mol)
and is provided with this table.
Additional ﬁle 3: Deﬁnition and overview of objectives and
constraints for simulation of metabolic and physiological functions of
the cardiomyocyte. To ensure consistency and full functionality of the
metabolic network, we performed a critical testing of physiological
functions based on knowledge of the cardiac metabolism by using ﬂux
balance analysis. The table lists all objectives and applied constraints as
used in the optimization problem. Furthermore, constraints as used in
functional pruning of the network are given. Abbreviations for constraints
as used in simulations with FASIMU software are as follows: (+), secretion of
the metabolite is allowed or the metabolite is product; (-), uptake of the
metabolite is allowed or metabolite is substrate and (=), secretion and
uptake of the metabolite is allowed or metabolites is either product or
substrate.
Additional ﬁle 4: Flux distributions of metabolic and physiological
functions of cardiomyocyte. To ensure consistency and full functionality
of the metabolic network, we performed a critical testing of physiological
functions based on knowledge of the cardiac metabolism by using ﬂux
balance analysis. Flux distributions listed in this table have been predicted
for each metabolic objective as deﬁned in Additional ﬁle 5. Abbreviations
for compartments: ext - external, cyto - cytosol, mito - mitochondrion, lyso
- lysosome, peroxy - peroxisome, micro - microsome.
Additional ﬁle 5: Metabolic network of the human cardiomyocyte in
SBML format.
Additional ﬁle 6: Testing functionality of Human heart model. A
comparison of the metabolic network to a previously reported
genome-scale reconstruction of the human heart [25] was performed. The
presented physiological functions of the cardiomyocyte (see Additional ﬁle
13) were applied to test the functionality of the partial network of the
human heart and compare the performance of both networks. From 110
tested functions 53 were found to have no feasible solution, this included
important cellular functions such as the citric acid cycle.
Additional ﬁle 7: Deﬁnition and overview of constraints for
simulations as used in the optimization problems for varied substrate
availability. Constraints listed in this table were applied in simulations for
varied substrate availability. For all three simulation settings the
corresponding target function and applied constraints are given. The
simulation settings include, ﬁrst, simulations of substrate uptake rates for
four diﬀerent substrates and oxygen demands while satisfying a baseline
ATP consumption rate. Second, simulations of substrate uptake rates for
four diﬀerent substrates and oxygen demands as under experimental
conditions while satisfying the same baseline ATP consumption rate. Finally,
simulations of substrate uptake rates for nine diﬀerent substrates and
oxygen demands while satisfying a predeﬁned metabolic target function.
Additional ﬁle 8: Predicted metabolic ﬂuxes of substrate uptake and
oxygen demand for ATP expenditure in varied substrate availability,
Ci+ > 0.6.We simulated a varied substrate availability for four selected
substrates, including glucose, oleate, acetoacetate and lactate while
demanding a baseline ATP consumption rate (vATPase) of 21.6
mmol · min−1 · (l cell)−1. This table lists uptake rates for oxygen, glucose,
oleate, acetoacetate, lactate and the resulting total substrate uptake rate
for each simulated substrate composition. Eﬃciency indices (Ci+ ) were
separately calculated for each simulation. Results are shown for calculated
eﬃciency values (Ci+ ) greater than 0.6 and given in descending order.
Additional ﬁle 9: Predicted metabolic ﬂuxes of substrate uptake and
oxygen demand for ATP expenditure in varied substrate availability,
Ci+ < 0.6. See caption of Additional ﬁle 8 but results are shown for
calculated eﬃciency values (Ci+ ) equal or less than 0.6.
Additional ﬁle 10: Alternate optima. To identify alternate ﬂux solutions
that can equally satisfy the problem, i.e. yield the same optimal solution,
we performed additional simulations. The MILP was re-solved after adding
a constraint (z*) for a single ﬂux of the original ﬂux distribution which was
set to either 1.01-fold (z∗1 ) or 0.99-fold (z∗2 ) of its original calculated ﬂux
value (v0). The optimization problem was repeated with substrate
combinations which were identiﬁed with the highest or lowest eﬃciency
value while satisfying (1) a baseline ATP consumption rate and (2) a target
function of the cardiomyocyte. This table includes all calculated ﬂux
solutions yielding the same optimal solution as with the original
optimization problem. Furthermore, an overview is given of alternate ﬂux
solutions for ﬂuxes representing external substrate and oxygen uptake.
Statistical signiﬁcance between ﬂux solutions for the analysis of alternate
ﬂux solutions was determined by use of 1-way ANOVA.
Additional ﬁle 11: Predicted metabolic ﬂuxes of substrate uptake
and oxygen demand for fulﬁlling the metabolic target function in
varied substrate availability,Ci+ > 0.8.We simulated a varied
substrate availability for nine selected substrates, including glucose,
palmitate, stearate, oleate, alpha-linoleate, eicosapentaenoate,
docosahexaenoate, acetoacetate and lactate. During the simulations, we
demanded an ATP expenditure (vATPase) of 21.6mmol · min−1 · (l cell)−1
and metabolic target ﬂux, as speciﬁed in Additional ﬁle 6. This table lists
results for substrate combination for which eﬃciency values (Ci+ ) greater
than 0.8 were calculated. Uptake rates for all nine substrates, the resulting
total substrate uptake rate and oxygen consumption rate for all simulated
substrate compositions which fulﬁlled the metabolic objective are given.
Furthermore solutions for glycogen synthesis and glycogenolysis as
determined during simulations are shown.
Additional ﬁle 12: Predictedmetabolic ﬂuxes of substrate uptake and
oxygen demand for fulﬁlling the metabolic target function in varied
substrate availability,Ci+ < 0.8. See caption of Additional ﬁle 7 but
results are shown for calculated eﬃciency values (Ci+ ) equal or less than 0.8.
Additional ﬁle 13: Gene expression annotation. The identiﬁcation of
human heart tissue speciﬁc reactions requires a tissue speciﬁc gene
expression proﬁle. We obtained gene expression samples from diﬀerent
gene expression data available from Gene Expression Omnibus, including
GDS181 and GSE1145. This table provides gene expression information
annotated to metabolic reactions of the cardiomyocyte network. Each
reaction identiﬁer refers to a compartment localisation of the respective
metabolic reaction. Furthermore, each entry in the table provides
information about annotated Ensemble Gene ID, Geo Dataset ID, Geo
Sample ID, Probeset ID, Gene ID, gene expression value and detection call.
The information of gene expression status can be obtained from the
column “Detection call”. Each expression is either categorized as present
(P), absent (A) or M (marginal). We further considered genes as expressed
for gene expression values with a cut-oﬀ greater than 100.
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